
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
无锡药明康德新药开发股份有限公司是一家主要提供新药研发、生产与配套服务以及相关技术平台服务的中国投资控股公司。该公司主要发现、研发及生产小分子药物、细胞疗法及基因疗法,以及提供医疗器械测试服务。该公司主要通过四个业务部门运营,包括中国区实验室服务部门、合约生产组织/合约研发及生产组织服务(CMO/CDMO服务)部门、美国区实验室服务部门以及临床研究服务部门。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Qing Yang | 52 | 2017 | Co-CEO & Executive Director |
Minzhang Chen | 53 | 2015 | Co-CEO & Executive Director |
He Liang | 56 | 2017 | Chairman of the Supervisory Committee |
Zhaohui Zhang | 55 | 2002 | COO of China, Executive VP & Executive Director |
Shaohua Lu-Wong | 56 | 2007 | Independent Non-Executive Director |
Zhiling Zhan | 62 | 2023 | Independent Non-Executive Director |
Wei Yu | 72 | 2023 | Independent Non-Executive Director |
Xuesong Leng | 55 | 2024 | Independent Non-Executive Director |
Wu Yibing | 58 | 2017 | Non-Executive Director |
Xiaomeng Tong | 52 | 2017 | Non-Executive Director |
Xin Zhang | 48 | 2023 | Independent Non-Executive Director |
Edward Hu | 63 | 2008 | Global Chief Investment Officer & Vice Chairman |
Ge Li | 58 | 2000 | Co-Founder, Executive Chairman, President & CEO |
Wu Baiyang | 62 | 2020 | Supervisor |
Zhu Minfang | 54 | 2017 | Employee Representative Supervisor |
Xiaomeng Tong | 51 | 2017 | - |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核